InVivoMAb anti-mouse CD8alpha
BE0061
ApplicationsWestern Blot, Other Application
Product group Antibodies
ReactivityMouse
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-mouse CD8alpha
- Delivery Days Customer7
- ApplicationsWestern Blot, Other Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID2.43
- Concentration4-11 mg/ml
- Estimated Purity≥95% , Determined by SDS-PAGE
- HostRat
- IsotypeIgG2b
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC41116161
References
- Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. Balogh KN et al., 2018, PLoS OneRead this paper
- Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Li J et al., 2018 Apr 17, ImmunityRead this paper
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Moynihan KD et al., 2016 Dec, Nat MedRead this paper
- TGFbeta Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Vanpouille-Box C et al., 2015 Jun 1, Cancer ResRead this paper
- IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Coffelt SB et al., 2015 Jun 18, NatureRead this paper
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C et al., 2015 Apr 16, NatureRead this paper
- Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Yamada DH et al., 2015 Feb 17, ImmunityRead this paper
- Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE et al., 2015 Jun, Cancer Immunol ResRead this paper
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. Voron T et al., 2015 Feb 9, J Exp MedRead this paper
- Intratumoral administration of mRNA encoding a fusokine consisting of IFN-beta and the ectodomain of the TGF-beta receptor II potentiates antitumor immunity. Van der Jeught K et al., 2014 Oct 30, OncotargetRead this paper
